194 related articles for article (PubMed ID: 36690550)
1. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
Amin NB; Saxena AR; Somayaji V; Dullea R
Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
[TBL] [Abstract][Full Text] [Related]
3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
Gluchowski NL; Gabriel KR; Chitraju C; Bronson RT; Mejhert N; Boland S; Wang K; Lai ZW; Farese RV; Walther TC
Hepatology; 2019 Dec; 70(6):1972-1985. PubMed ID: 31081165
[TBL] [Abstract][Full Text] [Related]
5. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
[TBL] [Abstract][Full Text] [Related]
6. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
Sawant-Basak A; Bergman AJ; Mancuso J; Tripathy S; Gosset JR; Mendes da Costa L; Esler WP; Calle RA
Clin Transl Sci; 2024 Feb; 17(2):e13687. PubMed ID: 38362827
[TBL] [Abstract][Full Text] [Related]
7. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
[TBL] [Abstract][Full Text] [Related]
8. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis.
Yenilmez B; Wetoska N; Kelly M; Echeverria D; Min K; Lifshitz L; Alterman JF; Hassler MR; Hildebrand S; DiMarzio C; McHugh N; Vangjeli L; Sousa J; Pan M; Han X; Brehm MA; Khvorova A; Czech MP
Mol Ther; 2022 Mar; 30(3):1329-1342. PubMed ID: 34774753
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
[TBL] [Abstract][Full Text] [Related]
10. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
[TBL] [Abstract][Full Text] [Related]
11. Role of diacylglycerol O-acyltransferase (DGAT) isoforms in bovine hepatic fatty acid metabolism.
Yang W; Wang S; Loor JJ; Lopes MG; Zhao Y; Ma X; Li M; Zhang B; Xu C
J Dairy Sci; 2022 Apr; 105(4):3588-3600. PubMed ID: 35181144
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
13. The Postnatal Resolution of Developmental Toxicity Induced by Pharmacological Diacylglycerol Acyltransferase 2 (DGAT2) Inhibition During Gestation in Rats.
Catlin NR; Bowman CJ; Campion SN; Lewis EM; Nowland WS; Stethem C; Cappon GD
Toxicol Sci; 2022 Sep; 189(2):225-236. PubMed ID: 35866640
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis.
Turchetto-Zolet AC; Maraschin FS; de Morais GL; Cagliari A; Andrade CM; Margis-Pinheiro M; Margis R
BMC Evol Biol; 2011 Sep; 11():263. PubMed ID: 21933415
[TBL] [Abstract][Full Text] [Related]
15. Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells.
Wurie HR; Buckett L; Zammit VA
FEBS J; 2012 Sep; 279(17):3033-47. PubMed ID: 22748069
[TBL] [Abstract][Full Text] [Related]
16. Histone Demethylase KDM7A Contributes to the Development of Hepatic Steatosis by Targeting Diacylglycerol Acyltransferase 2.
Kim JH; Nagappan A; Jung DY; Suh N; Jung MH
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681759
[TBL] [Abstract][Full Text] [Related]
17. Differential actions of diacylglycerol acyltransferase (DGAT) 1 and 2 in regulating lipid metabolism and progesterone secretion of goose granulosa cells.
Hu S; Gao S; Zhu J; Gan X; Chen X; He H; Liang L; Hu B; Hu J; Liu H; Han C; Kang B; Xia L; Wang J
J Steroid Biochem Mol Biol; 2020 Sep; 202():105721. PubMed ID: 32565248
[TBL] [Abstract][Full Text] [Related]
18. Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice.
Takemoto K; Fukasaka Y; Yoshimoto R; Nambu H; Yukioka H
Physiol Rep; 2020 Aug; 8(15):e14542. PubMed ID: 32786057
[TBL] [Abstract][Full Text] [Related]
19. Dietary Macronutrient Composition Determines the Contribution of DGAT1 to Alcoholic Steatosis.
Huang LS; Yuen JJ; Trites MJ; Saha A; Epps CT; Hu Y; Kerolle S; Lee SA; Jiang H; Goldberg IJ; Blaner WS; Clugston RD
Alcohol Clin Exp Res; 2018 Dec; 42(12):2298-2312. PubMed ID: 30192394
[TBL] [Abstract][Full Text] [Related]
20. Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis.
Jin Y; McFie PJ; Banman SL; Brandt C; Stone SJ
J Biol Chem; 2014 Oct; 289(41):28237-48. PubMed ID: 25164810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
